Endometrial Pipelle Biopsy Computer-Aided Diagnosis: A Feasibility Study.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
PMID:

Abstract

Endometrial biopsies are important in the diagnostic workup of women who present with abnormal uterine bleeding or hereditary risk of endometrial cancer. In general, approximately 10% of all endometrial biopsies demonstrate endometrial (pre)malignancy that requires specific treatment. As the diagnostic evaluation of mostly benign cases results in a substantial workload for pathologists, artificial intelligence (AI)-assisted preselection of biopsies could optimize the workflow. This study aimed to assess the feasibility of AI-assisted diagnosis for endometrial biopsies (endometrial Pipelle biopsy computer-aided diagnosis), trained on daily-practice whole-slide images instead of highly selected images. Endometrial biopsies were classified into 6 clinically relevant categories defined as follows: nonrepresentative, normal, nonneoplastic, hyperplasia without atypia, hyperplasia with atypia, and malignant. The agreement among 15 pathologists, within these classifications, was evaluated in 91 endometrial biopsies. Next, an algorithm (trained on a total of 2819 endometrial biopsies) rated the same 91 cases, and we compared its performance using the pathologist's classification as the reference standard. The interrater reliability among pathologists was moderate with a mean Cohen's kappa of 0.51, whereas for a binary classification into benign vs (pre)malignant, the agreement was substantial with a mean Cohen's kappa of 0.66. The AI algorithm performed slightly worse for the 6 categories with a moderate Cohen's kappa of 0.43 but was comparable for the binary classification with a substantial Cohen's kappa of 0.65. AI-assisted diagnosis of endometrial biopsies was demonstrated to be feasible in discriminating between benign and (pre)malignant endometrial tissues, even when trained on unselected cases. Endometrial premalignancies remain challenging for both pathologists and AI algorithms. Future steps to improve reliability of the diagnosis are needed to achieve a more refined AI-assisted diagnostic solution for endometrial biopsies that covers both premalignant and malignant diagnoses.

Authors

  • Sanne Vermorgen
    Department of Pathology, Radboudumc, Nijmegen, the Netherlands.
  • Thijs Gelton
    Department of Pathology, Radboudumc, Nijmegen, the Netherlands.
  • Peter Bult
    Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Heidi V N Kusters-Vandevelde
    Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.
  • Jitka Hausnerová
    Department of Pathology, University Hospital Brno, Brno, Czech Republic.
  • Koen Van de Vijver
    Department of Pathology, UZ Gent, Gent, Belgium.
  • Ben Davidson
    Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway; University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.
  • Ingunn Marie Stefansson
    Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway; Department of Pathology, Haukeland University Hospital Bergen, Bergen, Norway.
  • Loes F S Kooreman
    Department of Pathology, GROW School for Oncology and Develop-mental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Adelina Qerimi
    Department of Pathology, ViraTherapeutics GmbH, Innsbruck, Austria.
  • Jutta Huvila
    Department of Pathology, University of British Columbia, Vancouver, Canada; Department of Pathology, University of Turku, Turku, Finland.
  • Blake Gilks
    Department of Pathology, University of British Columbia, Vancouver, Canada.
  • Maryam Shahi
    Department of Pathology, Mayo Clinic, Rochester, Minnesota.
  • Saskia Zomer
    Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.
  • Carla Bartosch
    Department of Pathology, Portuguese Oncology Institute Lisbon, Lisbon, Portugal.
  • Johanna M A Pijnenborg
    Department of Gynecology, Radboudumc, Nijmegen, the Netherlands.
  • Johan Bulten
    Department of Pathology, Radboudumc, Nijmegen, the Netherlands.
  • Francesco Ciompi
    Diagnostic Image Analysis Group, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: francesco.ciompi@radboudumc.nl.
  • Michiel Simons
    Department of Pathology, Radboudumc, Nijmegen, the Netherlands. Electronic address: Michiel.Simons@radboudumc.nl.